Astellas secures option to license Audax's IL-12 immuno-oncology candidate in a deal worth up to $1.34 billion.

Recent court rulings and USPTO guidance reshape how biotech startups should approach patent strategy for drugs and ...

Flagship has merged 3 of its own portfolio companies into a single powerhouse aimed at predicting how drugs will work before ...

A ten-member European consortium led by Exogenus Therapeutics has secured $14.4 million to develop a disease-modifying ...

Intellectual property enforcement in the life sciences sector is evolving rapidly overall, and in no small part due to ...

EUCROF says the upcoming Ukrainian CRO Association will help show the country remains a strong location for drug trials ...

Kos Biotechnology invests in Golden Age Health to widen rare disease access in Asia-Pacific.

Ferring Pharmaceuticals is set to acquire Gameto, a cell engineering company working on new fertility treatments.

BMS halted the study earlier this year following three patient deaths in a competitor’s trial.

Roche has signed a strategic collaboration and license agreement with China's Hansoh Pharma to develop a portfolio of ...

New SCRS dashboard measures sponsor and CRO engagement with research sites, offering data-driven insight into partnership ...

Hematology research now needs new evidence strategies as targeted therapies create smaller, more specialized patient groups today ...